Talecris Initiates Clinical Development Program Evaluating Plasmin for Dissolving Blood Clots and Restoring Blood Flow in Legs

Talecris Biotherapeutics, Inc. announced that the first patient has been enrolled in its Phase I/Phase II clinical trial investigating the ability of Plasmin to treat acute Peripheral Arterial Occlusion (aPAO). In patients with aPAO, arterial blood flow to extremities, usually the legs, becomes blocked by a blood clot. Plasmin is a locally acting fibrin-binding thrombolytic derived from human plasma that can be infused directly into a clot via a catheter using minimally invasive techniques. Plasmin will be tested in patients with recent (within two weeks) onset or worsening of symptoms resulting from a blood clot in a leg artery or arterial bypass graft.

...

Want to see the full article?

• Purchase this article for only $3.00